☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 46-3218129 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdicti ...

Financial Performance - The net loss for the three months ended September 30, 2020, was $8.8 million, an increase of $2.6 million compared to a net loss of $6.2 million for the same period in 2019[100]. - For the nine months ended September 30, 2020, total operating expenses were $24.4 million, an increase of $5.2 million from $19.3 million in the same period of 2019[105]. - The accumulated deficit as of September 30, 2020, was $99.4 million, with continuous losses since the company's inception in March 2013[87]. - Net cash used in operating activities for the nine months ended September 30, 2020, was $22.4 million, compared to $16.9 million for the same period in 2019[118]. - The company expects to incur substantial additional losses in the future as it expands its research and development activities[112]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2020, were $6.0 million, up from $4.9 million in the same period of 2019, reflecting a $1.1 million increase[101]. - Research and development expenses for the nine months ended September 30, 2020, totaled $17.8 million, compared to $15.1 million for the same period in 2019, reflecting a $2.7 million increase[107]. - The company plans to increase research and development expenses for the foreseeable future, although it cannot reasonably estimate the costs or timelines for product development and commercialization[111]. General and Administrative Expenses - General and administrative expenses increased to $2.7 million for the three months ended September 30, 2020, compared to $1.5 million for the same period in 2019, marking a $1.2 million rise[104]. - General and administrative expenses increased to $6.7 million for the nine months ended September 30, 2020, up from $4.2 million in the same period of 2019, reflecting a $2.5 million rise primarily due to personnel-related costs and stock-based compensation[108]. Income and Cash Flow - Interest income, net for the three months ended September 30, 2020, was $40,000, down from $272,000 in the same period of 2019, a decrease of $232,000[104]. - Interest income, net decreased to $0.6 million for the nine months ended September 30, 2020, down from $1.0 million in the same period of 2019, driven by reduced income from cash investments[108]. - Cash and cash equivalents as of September 30, 2020, were $373.1 million, with an accumulated deficit of $99.4 million[110]. - The company raised $243.5 million in gross proceeds from its IPO in September 2020, with net proceeds of $223.2 million after deducting underwriting discounts and commissions[110]. - Investing activities provided $28.0 million of cash during the nine months ended September 30, 2020, primarily from maturities of marketable securities[120]. - Financing activities generated $294.3 million in cash during the nine months ended September 30, 2020, mainly from the IPO and Series D Preferred Stock issuance[122]. Future Outlook - The company does not currently have any product candidates in clinical trials or approved for sale, and it expects to incur significant losses for the foreseeable future[88]. - The company anticipates that operating expenses will increase significantly as it advances product candidates through development and seeks regulatory approval[87]. - The company has not generated any revenue from product sales and does not expect to do so for several years[110].